Pivot3 Brings its Hyper-Converged Infrastructure Technology to VMware vSphere
Pivot3, a pioneer and innovator in the development of hyper-converged infrastructure (HCI), today announced it will bring its HCI technology to VMware vSphere® 6.
VMware vSphere 6 is the industry-leading virtualization platform for the hybrid cloud and the foundation for the software-defined data center. VMware vSphere 6 provides customers with a highly available, resilient, on-demand cloud infrastructure to run, protect and manage any application.
The newest edition of Pivot3’s patented vSTAC OS software, vSTAC OS 7 which uses patented Scalar Erasure Coding technology, is now built on a foundation of VMware vSphere 6 which enables GPU virtualization, higher fault tolerance and greater availability on Pivot3’s HCI platforms.
The upcoming release of the vSTAC OS Management Client Integration Plug-In integrates with the VMware vSphere 6 Web Client interface to enable users to manage their entire Pivot3 hyper-converged array of nodes which scales to petabytes of storage and millions of Input/Output Operations Per Second (IOPS) – all from a central console.
Pivot3’s global hyper-converged infrastructure solution helps enterprises achieve low total cost of ownership by providing combined virtualized shared storage and compute power on the same platform, eliminating the need for separate physical storage area networks (SANs) and servers. The streamlined vSTAC OS 7 dashboard provides VMware server administrators and application owners with an easy-to-manage status view and control console for the combined Pivot3 virtual SAN and compute environment.
“Pivot3’s HCI provides the performance and high-availability of shared storage without the need for expensive external storage arrays,” said Ron Nash, CEO of Pivot3. “With Pivot3 global HCI, growing enterprises and organizations with multiple locations, such as remote or branch offices (ROBOs), can deploy critical applications and associated data onsite so that they are available at all times without needing access to company-wide networks.”
Pivot3 also supports End User Computing (EUC) licensing of VMware Horizon® 6 for desktop virtualization. VMware Horizon provides end-users access to all of their virtual desktops, applications and online services through a single workspace.
“Pivot3’s HCI with VMware vSphere 6 provides enterprise customers with a scale-out, distributed storage architecture,” said Howard Hall, senior director, Global Technology Partner Organization, VMware. “Pivot3's efficient, high-performance infrastructure combining storage and compute capabilities with VMware vSphere can accelerate time to value for organizations, which means that they can now deploy their solution much faster with less specialized expertise, all at a lower cost. The result is that customers can benefit from increased CPU power to more efficiently run advanced VMware vSphere 6 features.”
Pivot3, with its efficient and scalable HCI, has been a VMware supporter since 2008. The immediate support for VMware vSphere 6 builds on Pivot3’s longstanding partnership with VMware, which includes support for VMware Horizon and VMware Mirage™, as well as 100 percent reliance on VMware vSphere.
Pivot3 has 1,600 customers around the world. Enterprise customers who buy Pivot3 HCI also buy Enterprise and Enterprise Plus licenses from VMware. Pivot3 is also an Original Equipment Manufacturer (OEM) and Technology Alliance Partner, and is a top tier sponsor of VMware User Group and VMware vForum.
Founded in 2002, Pivot3 provides patented global hyper-convergence technology that saves an extraordinary amount of space, ensures fault tolerance, drives down complexity and cost and dramatically increases scale-out performance. Today, Pivot3 has more than 1,600 customers around the world deploying more than 13,000 globally hyper-converged infrastructure appliances in multiple industries, such as video surveillance, healthcare, government, transportation, entertainment, education, gaming and retail. The company has won numerous awards and was most recently featured by CRN in their top 50 Virtualization list for 2014. To learn more about Pivot3, visit http://www.pivot3.com.
VMware, vSphere, Horizon, and Mirage are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions. The use of the word “partner” or “partnership” does not imply a legal partnership relationship between VMware and any other company.
Allison Francis, 972-235-3439
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom